Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Rosen who wrote (879)	11/23/1997 2:15:00 AM
From: Cacaito	Read Replies (1) \| Respond to of 7041

Bruce, it seems that there is a court problem cooking between HVSF and Vivus. Vivus is the only company with a urethral delivery method and with a sound patent. If this patent could be challenged, definitely more complex than the "oral method", anyone could challenge Zona's patent. I think this is a very interesting development, Vivus got the patent, they already had a fight on it before and they end up in compensating the other part, but they did prevailed. Also, of interest was the Nxtr challenge to Lipo, regarding lyophilized liposomes, and Lipo won $2 millions, oh they also won a small royalty (less than 1% is the rumor)and Lipo expended (waste?) $10,000,000 in the fight. Of course, with Schering behind, they probably will have muscle for a better fight. But, as I said before, Barr Labs fights complex patents and go succesfully ahead with generics (recent Barr victories over AZT/GlaxoWellcome, coumadin/DupontMerck and the most recent Premarin/Amer Home Products) showed how difficult is to fight for the patent holders.